Caris Life Sciences Signals Strong Growth and Ambition

Caris Life Sciences, Inc. ((CAI)) has held its Q4 earnings call. Read on for the main highlights of the call.

Caris Life Sciences’ latest earnings call struck an upbeat tone, with management emphasizing powerful revenue growth, margin expansion and a turn to sustained cash generation. Executives balanced that optimism with caution around early multi‑cancer early detection data, reimbursement dynamics and a planned step‑up in spending that could introduce some near‑term volatility.

Record Revenue Growth Underlines Demand for Profiling

Caris posted Q4 revenue of $293 million, a 125% jump from a year ago, capping full‑year growth of roughly 97%. Molecular profiling remains the core engine, with Q4 profiling revenue soaring 199% to $282 million and full‑year profiling revenue climbing 120% to $766.7 million.

Profitability and Cash Flow Turn Positive

The company delivered Q4 GAAP net income of $82 million and adjusted EBITDA of $106 million, alongside free cash flow of $39.7 million. For the full year, adjusted EBITDA reached $138 million and free cash flow $67 million, helping lift cash on hand to just above $800 million.

Margin Expansion Signals Operating Leverage

Gross profitability improved sharply, with Q4 GAAP gross margin rising to 75% from 54% a year earlier and 68% in Q3. For the year, GAAP molecular profiling gross margin finished around 66%, or 64% excluding additional collections from prior periods, highlighting meaningful operating leverage as volumes and pricing scale.

Volume Growth Paired With ASP Upside

Clinical profiling volumes reached about 199,300 cases in 2025, up roughly 22% year over year, with Q4 volumes rising 20% sequentially. At the same time, the company reported a 150% clinical ASP increase, with full‑year tissue ASP around $3,876 and blood ASP just above $2,500, both showing strong double‑digit percentage gains.

Scaling Platform and Data Assets

Management highlighted a key milestone of more than 1 million profiled cases and over 50 billion molecular markers in its database. That dataset spans about 627,000 exomes, 678,000 transcriptomes and 740,000 match profiles, strengthening the company’s hand in product development and biopharma collaborations.

Encouraging Interim Caris Detect (ACHIEVE‑1) Data

Interim ACHIEVE‑1 results for the Caris Detect multi‑cancer early detection test showed combined Stage I/II sensitivity of 63.1% and an overall AUC of 0.90. Specificity ran high, at 99.1% in the screening cohort and 95.3% in a higher‑risk normal cohort, with sensitivity improving at later cancer stages.

Commercial Momentum and Broader Coverage

MI Cancer Seek now accounts for more than 70% of tissue volume for the year and over 75% in Q4, and the program covers more than 225 million lives. Therapy‑selection volumes rose about 20% in Q4 and 22% for the year, while Caris Assure posted 59% year‑over‑year growth in Q4.

Guidance: Growth, Investments and Cash Discipline

For 2026, Caris guided revenue to $1.00–$1.02 billion, implying 23%–26% growth driven by roughly 20% therapy‑selection volume gains and 21%–22% molecular profiling growth. Management plans $60 million in CapEx and GAAP operating expenses of $590–$595 million, yet still expects to stay positive on adjusted EBITDA and free cash flow on the back of its $800‑plus million cash balance.

Strategic Spending Plan Raises Execution Stakes

The company will reinvest aggressively, boosting its salesforce by roughly 20%–25% while funding ACHIEVE‑2, minimal residual disease programs and early detection infrastructure. This includes capacity buildouts and equipment such as new sequencing systems, designed to position Caris for a potential MCED launch as data mature.

Interim MCED Data Still Need Validation

Management stressed that ACHIEVE‑1 is an interim, case‑control study with limited follow‑up and small sample sizes for several tumor types, which tempers the interpretation of lineage‑specific results. A blinded holdout cohort and the larger ACHIEVE‑2 study must be completed before the test can be broadly commercialized and fully accepted by physicians and payers.

Pharma Revenue Cadence Remains Uneven

Pharma and research services showed softness earlier in the year despite a $10.8 million contribution in Q4, and management cautioned that revenue in this segment is inherently lumpy. Growth will depend on converting a growing pipeline of deals, including the recently announced collaboration with Genentech and other companion diagnostics projects.

Reimbursement and Pricing Add Uncertainty

Final revenue came in about $12 million above preliminary estimates due to better‑than‑expected payer collections, underscoring sensitivity to reimbursement. With 25% of tissue volume still outside the PLA code and ongoing Medicare coding and pricing rules in play, both upside and risk remain around future ASPs.

Rising OpEx and CapEx Pressure Near‑Term Visibility

Caris plans to lift GAAP operating expenses by roughly 19%–20% in 2026 and nearly quadruple CapEx to around $60 million, which could compress margins if growth slows. While management reiterated its commitment to positive adjusted EBITDA and free cash flow, the absence of a precise EBITDA range leaves some uncertainty for near‑term earnings.

Small Cohorts Limit Lineage‑Level Confidence

Although overall Caris Detect performance appears promising, Stage I/II sensitivity for specific cancers like pancreas and head and neck is based on very small patient numbers. Investors should expect physicians and payers to demand larger, more robust datasets before granting broad adoption or premium reimbursement for these indications.

Caris Life Sciences ended the call projecting confidence that its strong revenue momentum, expanding margins and large cash reserve can support heavy investment without sacrificing profitability. Investors will now watch whether the company can execute on its ambitious spending plans, validate its MCED platform and navigate reimbursement complexities while keeping its growth story intact.